$62.1 B

AGN Mkt cap, 15-Oct-2018
Allergan Net income (Q2, 2018)-754 M

Allergan Income Statement

Quarterly

USDQ2, 2018

General and administrative expense

630.0m

Operating expense total

630.0m

Net Income

(754.0m)

Allergan Balance Sheet

Annual

USDFY, 2013FY, 2014

Cash

3.0b4.9b

Accounts Receivable

883.3m914.5m

Inventories

285.3m296.0m

Current Assets

5.3b6.9b

PP&E

923.2m1.0b

Goodwill

2.3b2.4b

Total Assets

10.6b12.4b

Accounts Payable

283.2m287.4m

Short-term debt

55.6m72.1m

Current Liabilities

1.2b1.6b

Long-term debt

2.1b2.1b

Total Debt

2.2b2.2b

Additional Paid-in Capital

3.0b3.4b

Retained Earnings

4.6b5.9b

Total Equity

6.5b7.8b

Debt to Equity Ratio

0.3 x0.3 x

Debt to Assets Ratio

0.2 x0.2 x

Financial Leverage

1.6 x1.6 x

Quarterly

USDQ1, 2018Q2, 2018

Current Liabilities

5.8b

Total Equity

72.3b71.3b

Allergan Cash Flow

Annual

USDFY, 2013FY, 2014

Net Income

988.7m1.5b

Depreciation and Amortization

254.6m248.1m

Inventories

(27.0m)(44.0m)

Accounts Payable

37.4m1.9m

Cash From Operating Activities

1.7b1.9b

Purchases of PP&E

(171.9m)(243.9m)

Cash From Investing Activities

(1.4b)182.7m

Cash From Financing Activities

28.2m(204.0m)

Income Taxes Paid

455.3m487.8m
Report incorrect company information